DDInter148 DDInter1376
Azacitidine is a pyrimidine nucleoside analogue with anti-neoplastic activity. It differs from cytosine by the presence of nitrogen in the C5-position, key in its hypomethylating activity.[A1406,A1413,A1415] Two main mechanisms of action have been proposed for azacitidine. One of them is the induction of cytotoxicity. As an analogue of cytidine, it is able to incorporate into RNA and DNA, disrupting RNA metabolism and inhibiting protein and DNA synthesis. The other one is through the inhibition of DNA methyltransferase, impairing DNA methylation. Due to its anti-neoplastic activity and its ability to inhibit methylation in replicating DNA, azacytidine has been used mainly used in the treatment of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), two types of cancer characterized by the presence of aberrant DNA methylation.[
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Azacitidine {u} (Compound) resembles {v} (Compound) Adenosine
Azacitidine {u} (Compound) resembles {v} (Compound) S-Adenosylmethionine
Azacitidine {u} may lead to a major life threatening interaction when taken with {v} Cladribine
Azacitidine {u} (Compound) binds {v} (Gene) DNMT3A
Azacitidine {u} (Compound) upregulates {v} (Gene) FOXJ3
Azacitidine {u} (Compound) is included by {v} (Pharmacologic Class) Nucleic Acid Synthesis Inhibitors
Azacitidine {u} (Compound) downregulates {v} (Gene) ANXA2
Azacitidine {u} (Compound) causes {v} (Side Effect) Neck pain
Azacitidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Candida albicans
Azacitidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Efalizumab
Azacitidine (Compound) resembles Adenosine (Compound)
Azacitidine (Compound) resembles S-Adenosylmethionine (Compound)
Azacitidine may lead to a major life threatening interaction when taken with Cladribine
Azacitidine (Compound) binds DNMT3A (Gene)
Azacitidine (Compound) upregulates FOXJ3 (Gene)
Azacitidine (Compound) is included by Nucleic Acid Synthesis Inhibitors (Pharmacologic Class)
Azacitidine (Compound) downregulates ANXA2 (Gene)
Azacitidine (Compound) causes Neck pain (Side Effect)
Azacitidine may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans
Azacitidine may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab